Fig. 2.
JNJ-47965567 does not alter clinical disease progression in SOD1G93A mice. a–d SOD1G93A mice were injected i.p. with JNJ-47965567 (30 mg/kg) or an equivalent volume of β-CD (vehicle) three times per week from disease onset until end stage disease. Mice were assessed for a ALS score, b body weight loss (percent of pre-disease maximum), c motor (rotarod) coordination and d survival. a–d Results are mean ± SEM (β-CD, n = 23; JNJ-47965567, n = 24) with differences between groups compared using a–c a two-way ANOVA or d the log-rank (Mantel-Cox) test